Secondly, through the use of a reconstituted catalytic tumor suppressor, DAPk-based fusion proteins are able to bypass resistance mechanisms, unlike Ang and GrB which are limited by the upregulation of their endogenous inhibitors in target cells. This evidence concerns the gene DAPK1 and neoplasm.